Heterogeneous Presentations and Serologies in Myasthenia Gravis Patients Presenting with Dysphagia
The Laryngoscope · 2024
DOI: 10.1002/lary.31601 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2024. Verfasst von Clare Moffatt und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head & Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A. Hauptthemen laut MEDLINE: Myasthenia Gravis, Deglutition Disorders, Receptors, Cholinergic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCD NIH HHS, National Institute on Deafness and Other Communication Disorders.
Themen: Dysphagie
Abstract (Originalsprache)
Introduction
Myasthenia gravis (MG) is an autoimmune disease that affects the neuromuscular junction. MG patients may present de novo with primary otolaryngology complaints, including swallowing dysfunction. This study describes a range of unique presentations and rare diagnostic serologies, which have not previously been fully described.
Methods
A retrospective review was performed of all patients presenting with primary symptom of dysphagia and subsequently diagnosed with MG. Data collected included demographics, clinical presentation, swallow studies, serology, imaging, treatment, and response.
Results
Five patients met the inclusion criteria. Four endorsed dysphagia as primary complaint and one endorsed dysphagia and dysphonia. All patients underwent in‐office swallow evaluations that showed vallecular or pyriform sinus residue. Three patients completed modified barium swallow studies that showed pharyngeal weakness and epiglottic dysfunction in all, and upper esophageal sphincter dysfunction in two. One patient with additional symptom of dyspnea was admitted and found to be in myasthenic crisis. Upon serologic evaluation, three patients were positive for acetylcholine receptor (AChR) antibodies only, one for muscle‐specific‐kinase (MuSK) antibodies only, and one for low density lipoprotein receptor‐related protein 4 (LRP4) antibodies only. All patients received neurology evaluation and were treated with steroids, pyridostigmine, plasma exchange, or rituximab. In three patients with over 1 year follow‐up, symptoms were significantly improved or resolved.
Conclusion
MG is an important differential diagnosis in patients with unexplained pharyngeal dysphagia. While workup can include AChR antibody screening, in seronegative patients with persistent symptoms, additional testing for MuSK and LRP4 may lead to diagnosis and effective treatment. Level of Evidence 4 Laryngoscope , 134:4903–4910, 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head & Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A.
- Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A.
ORCID-Profile: Clare Moffatt, Pranati Pillutla
Förderung
- NIDCD NIH HHS
- National Institute on Deafness and Other Communication Disorders
Zitieren
APA
Moffatt, C., Pillutla, P., Soltanzadeh, P., & Chhetri, D. K. (2024). Heterogeneous Presentations and Serologies in Myasthenia Gravis Patients Presenting with Dysphagia. The Laryngoscope. https://doi.org/10.1002/lary.31601
Vancouver
Moffatt C, Pillutla P, Soltanzadeh P, Chhetri DK. Heterogeneous Presentations and Serologies in Myasthenia Gravis Patients Presenting with Dysphagia. The Laryngoscope. 2024. doi:10.1002/lary.31601
BibTeX
@article{Moffatt2024,
author = {Moffatt, Clare and Pillutla, Pranati and Soltanzadeh, Payam and Chhetri, Dinesh K},
title = {Heterogeneous Presentations and Serologies in Myasthenia Gravis Patients Presenting with Dysphagia},
journal = {The Laryngoscope},
year = {2024},
doi = {10.1002/lary.31601}
}
EUVIMED